{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:42:05Z","timestamp":1792788125122,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn","id":[{"id":"https:\/\/ror.org\/01xnwqx93","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiparametric MRI has improved prostate cancer (PCa) diagnostics. The current standard combines MRI-targeted fusion biopsy (TB) with 12-core systematic biopsy (SB); current guidelines allow replacing SB with perilesional sampling (PB) penumbra to maintain diagnostic performance while reducing biopsy burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed 314 biopsy-naive men with Prostate Imaging Reporting and Data System (PI-RADS) 3\u20135 lesions who underwent transperineal MRI-fusion biopsy (TB plus 12-core systematic biopsy) under local anesthesia. A simulated PB strategy was evaluated post hoc by selecting four of the twelve systematic cores located in the directly adjacent sectors to the MRI-visible lesion on the standardized PI-RADS sector map and compared with SB. The primary objective was to assess whether PB replicates the diagnostic performance of SB for detecting clinically significant PCa (csPCa; ISUP grade group\u2009\u2265\u20092). We also compared biopsy and prostatectomy ISUP-grading, NCCN (National Comprehensive Cancer Network) -classification and the Briganti nomogram-based lymph-node metstasis risk. Statistical analyses used R and SPSS, with chi-square or Fisher\u2019s exact tests for categorial and t-tests for continuous variables; two-sided\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 was considered significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PCa was detected in 79.9% (251\/314) of men, including 68.8% (216\/314) with csPCa. TB alone detected 94.4% of csPCa, while SB detected 73.1%. The simulated TB\u2009+\u2009PB approach achieved 98.0% overall PCa detection and 99.1% csPCa detection (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.48 vs. TB\u2009+\u2009SB). Concerning the impact on NCCN risk assessment, ISUP grade distribution was comparable across TB-based strategies, whereas SB alone detected fewer cancers and showed a trend towards lower ISUP grades. In the prostatectomy subgroup, ISUP grade concordance did not differ significantly between TB\u2009+\u2009SB and TB\u2009+\u2009PB (both 62.0%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20091.0). Mean Briganti scores did not differ significantly between TB\u2009+\u2009SB and TB\u2009+\u2009PB, with a minimal absolute difference of 0.17%. A 75% reduction of biopsy cores would be reached by a replacement of SB with PB. There was no significant loss of detection for csPCa (ISUP grade group 2\u20135; 99.1%) and no association with a loss of diagnostic yield for all ISUP grade groups. 11% reduction in detected cases was confined to ISUP grade group 1 (Supplementary Table S2).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A TB plus 4-core PB may serve as an efficient alternative to conventional 12-core SB, without a significant reduction in diagnostic accuracy or a change in pretreatment risk assessment while markedly reducing procedural burden and resource use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-026-04606-x","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:12:02Z","timestamp":1790147522000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systematic versus perilesional sampling in transperineal MRI-fusion biopsy: is perilesional sampling ready for prime time? A high-volume center analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Agneta","family":"Seebold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Ellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Isaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian A.","family":"Luetkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Krausewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"2","key":"4606_CR1","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading. Am J Surg Pathol. 2016;40(2):244\u201352.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"4606_CR2","first-page":"521","volume":"78","author":"B Turkbey","year":"2020","unstructured":"Turkbey B, et al. Imaging techniques for prostate cancer: implications for clinical practice. Eur Urol. 2020;78(4):521\u201331.","journal-title":"Eur Urol"},{"issue":"19","key":"4606_CR3","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2025.3579","volume":"333","author":"A Kinnaird","year":"2025","unstructured":"Kinnaird A, et al. OPTIMUM Investigators. Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial. JAMA. 2025;333(19):1679\u201387. https:\/\/doi.org\/10.1001\/jama.2025.3579.","journal-title":"JAMA"},{"key":"4606_CR4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378:1767\u201377.","journal-title":"N Engl J Med"},{"key":"4606_CR5","unstructured":"European Association of Urology. EAU Guidelines on Prostate Cancer. 2024 Edition. https:\/\/uroweb.org\/guidelines\/prostate-cancer, accessed 12.12.2025."},{"key":"4606_CR6","unstructured":"German S, Guideline. Interdisciplinary Guideline on Prostate Cancer. 2023. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/prostatakarzinom, accessed 12.12.2025."},{"key":"4606_CR7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.eururo.2022.01.035","volume":"82","author":"WG Brisbane","year":"2022","unstructured":"Brisbane WG, et al. Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling. Eur Urol. 2022;82:303\u201310. https:\/\/doi.org\/10.1016\/j.eururo.2022.01.035.","journal-title":"Eur Urol"},{"key":"4606_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41391-022-00608-1","volume":"26","author":"JP Noujeim","year":"2023","unstructured":"Noujeim JP, et al. Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling. Prostate Cancer Prostatic Dis. 2023;26:575\u201382. https:\/\/doi.org\/10.1038\/s41391-022-00608-1.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4606_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.euros.2022.10.004","volume":"43","author":"MJ Hagens","year":"2022","unstructured":"Hagens MJ, et al. An MRI-directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: Less Is More. Eur Urol Open Sci. 2022;43:68\u201375. https:\/\/doi.org\/10.1016\/j.euros.2022.10.004.","journal-title":"Eur Urol Open Sci"},{"key":"4606_CR10","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.eururo.2018.10.012","volume":"75","author":"G Gandaglia","year":"2019","unstructured":"Gandaglia G, et al. A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with MRI-targeted and systematic biopsies. Eur Urol. 2019;75:506\u201314.","journal-title":"Eur Urol"},{"key":"4606_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.euros.2024.05.009","volume":"66","author":"F Zattoni","year":"2024","unstructured":"Zattoni F, et al. Enhancing prostate cancer detection accuracy in magnetic resonance imaging-targeted prostate biopsy: optimizing the number of cores taken. Eur Urel Open Sci. 2024;66:16\u201323.","journal-title":"Eur Urel Open Sci"},{"key":"4606_CR12","doi-asserted-by":"publisher","first-page":"7544","DOI":"10.1007\/s00330-022-08822-3","volume":"32","author":"D Deniffel","year":"2022","unstructured":"Deniffel D, et al. Prostate biopsy in the era of MRI-targeting: towards a judicious use of aaditional systematic biopsy. Eut Radiol. 2022;32:7544\u201353.","journal-title":"Eut Radiol"},{"key":"4606_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.urolonc.2018.10.009","volume":"37","author":"Y Freifeld","year":"2019","unstructured":"Freifeld Y, et al. Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy. Urol Oncol. 2019;37:57\u201362.","journal-title":"Urol Oncol"},{"key":"4606_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.urology.2016.11.017","volume":"102","author":"DJ Bryk","year":"2017","unstructured":"Bryk DJ, et al. The role of ipsilateral and contralateral transrectal ultrasound-guided systematic prostate biopsy in men with unilateral magnetic resonance imaging lesion undergoing magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy. Urology. 2017;102:178\u201383.","journal-title":"Urology"},{"key":"4606_CR15","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41391-023-00770-3","volume":"27","author":"A Zambon","year":"2024","unstructured":"Zambon A, et al. Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors. Prostate Cancer Prostatic Dis. 2024;27:500\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4606_CR16","doi-asserted-by":"publisher","first-page":"175628722211114","DOI":"10.1177\/17562872221111410","volume":"14","author":"A Jager","year":"2022","unstructured":"Jager A, et al. An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies. Ther Adv Urol. 2022;14:17562872221111410.","journal-title":"Ther Adv Urol"},{"key":"4606_CR17","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00261-023-03894-1","volume":"48","author":"M Ruan","year":"2023","unstructured":"Ruan M, et al. Novel sampling scheme with reduced cores in men with multiparametric MRI-visible lesions undergoing prostate biopsy. Abdom Radiol (NY). 2023;48:2139\u201347.","journal-title":"Abdom Radiol (NY)"},{"key":"4606_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.euros.2022.04.001","volume":"40","author":"MJ Hagens","year":"2022","unstructured":"Hagens MJ, et al. Diagnostic performance of a magnetic resonance imaging-directed targeted plus regional biopsy approach in prostate cancer diagnosis: a systematic review and meta-analysis. Eur Urol Open Sci. 2022;40:95\u2013104.","journal-title":"Eur Urol Open Sci"},{"issue":"4","key":"4606_CR19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S1470-2045(25)00091-9","volume":"26","author":"E Dinneen","year":"2025","unstructured":"Dinneen E, Almeida-Magana R, Al-Hammouri T, Pan S, Leurent B, Haider A, Freeman A, Roberts N, Brew-Graves C, Grierson J, Clow R, Williams N, Aning J, Walton T, Persad R, Oakley N, Ahmad I, Dutto L, Briggs T, Allen C, Tandogdu Z, Adshead J, Oxley J, Kelly J, Shaw G. NeuroSAFE PROOF Investigators. Effect of NeuroSAFE-guided robot-assisted radical prostatectomy versus standard robot-assisted radical prostatectomy on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial. Lancet Oncol. 2025;26(4):447\u201358.","journal-title":"Lancet Oncol"},{"key":"4606_CR20","doi-asserted-by":"publisher","unstructured":"Cannoletta D et al. Utility of MRI perilesional biopsy in prostate cancer: impact of the Prostate Imaging-Reporting and Data System and biopsy history. BJU Int. https:\/\/doi.org\/10.1111\/bju.70027. PMID: 41077924.","DOI":"10.1111\/bju.70027"},{"key":"4606_CR21","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.eururo.2014.08.079","volume":"67","author":"JD Le","year":"2015","unstructured":"Le JD, Tan N, Shkolyar E, et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount 3 histopathology. Eur Urol. 2015;67:562\u201376. https:\/\/doi.org\/10.1016\/j.eururo.2014.08.079.","journal-title":"Eur Urol"},{"key":"4606_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.eururo.2015.12.052","volume":"70","author":"JP Radtke","year":"2016","unstructured":"Radtke JP, Schwab C, Wolf MB, et al. Multiparametric magnetic resonance imaging (MRI) and MRI-transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen. Eur Urol. 2016;70:846\u201353.","journal-title":"Eur Urol"},{"key":"4606_CR23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503223","author":"MJ Roobol","year":"2025","unstructured":"Roobol MJ, de Vos II, M\u00e4nsson M, et al. ERSPC Investigators. European Study of Prostate Cancer Screening \u2013 23-Year Follow-up. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2503223.","journal-title":"N Engl J Med"},{"key":"4606_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0000000000001025","author":"L Bertelaccini","year":"2026","unstructured":"Bertelaccini L, La Vecchia C, Sardanelli F, et al. European Cancer Prevention Organization on cancer screening: an expert panel position paper. EurJ Cancer Prev. 2026. https:\/\/doi.org\/10.1097\/CEJ.0000000000001025.","journal-title":"EurJ Cancer Prev"},{"key":"4606_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2026.06.012","author":"F Sanguedolce","year":"2026","unstructured":"Sanguedolce F, et al. ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy. Eur Urol. 2026. https:\/\/doi.org\/10.1016\/j.eururo.2026.06.012.","journal-title":"Eur Urol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04606-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04606-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04606-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:02:30Z","timestamp":1790193750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04606-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4606"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04606-x","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"11 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the University Hospital Bonn. The requirement for written informed consent was waived by the Ethics Committee due to the retrospective nature of the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"378"}}